title: Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.
abstract: The acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymes DGAT1 and DGAT2 catalyze the final step in triglycerides biosynthesis. This study examined the relationships of baseline phenotypes and the common polymorphisms in DGAT1 and DGAT2 with the lipid responses to niacin.Lipid responses in Chinese patients with dyslipidemia treated with the extended release (ER) niacin/laropiprant combination 1000/20 mg for 4 weeks and then 2000/40 mg for 8 weeks (n = 121, the primary study) or with ER niacin 1500 mg for at least 4 weeks (n = 68, the replication study) were analyzed according to genotypes of DGAT1 rs7003945 T>C and DGAT2 rs3060 T>C polymorphisms.Treatment with ER niacin improved all lipid parameters in both studies. Absolute and percentage changes in lipids were related to their baseline levels, particularly for low-density lipoprotein cholesterol (LDL-C). The DGAT2 rs3060 T>C polymorphism was associated with lower baseline LDL-C, apoB, high-density lipoprotein cholesterol (HDL-C), and apoAI in patients on statin therapy in the primary study. Subjects with the DGAT2 rs3060 T>C variant had less reduction in LDL-C in the primary study and smaller changes in triglyceride and HDL-C in the replication study but these associations became non-significant after adjusting for baseline lipid values. The DGAT1 rs7003945 T>C polymorphism was not related to lipid baseline values or changes in either study. Concomitant statin therapy and lower body weight were also associated with greater reduction in LDL-C.Baseline lipid levels were the main determinants of lipid responses especially for LDL-C. The DGAT2 rs3060 polymorphism might influence the lipid responses depending on baseline phenotype, but this association did not persist after adjustment for the baseline lipid levels.
authors.affiliation: From the Department of Medicine and Therapeutics (MH, YLY, BT); Department of Surgery (CFN); School of Pharmacy, The Chinese University of Hong Kong, Hong Kong SAR (CPL, VWYL); Department of Medical Technology, Osaka University Hospital (HH); Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan (DM, SY); and Diabetes Center, Second Xiangya Hospital, Institute of Metabolism and Endocrinology, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan, China (YLY).
authors.forename: Miao
authors.initials: M
authors.lastname: Hu
authors.forename: Ya-Ling
authors.initials: YL
authors.lastname: Yang
authors.forename: Chi-Fai
authors.initials: CF
authors.lastname: Ng
authors.forename: Chui-Ping
authors.initials: CP
authors.lastname: Lee
authors.forename: Vivian W Y
authors.initials: VWY
authors.lastname: Lee
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hanada
authors.forename: Daisaku
authors.initials: D
authors.lastname: Masuda
authors.forename: Shizuya
authors.initials: S
authors.lastname: Yamashita
authors.forename: Brian
authors.initials: B
authors.lastname: Tomlinson
mesh_terms: D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D044466:Asian People / Q000235:genetics; D008078:Cholesterol, LDL / Q000097:blood; D051048:Diacylglycerol O-Acyltransferase / Q000235:genetics; D050171:Dyslipidemias / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use*; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D008055:Lipids; D014280:Triglycerides; D009525:Niacin; C494881:DGAT1 protein, human; C494885:DGAT2 protein, human; D051048:Diacylglycerol O-Acyltransferase